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Supplementary Figure and Table Legends 
 
  
Figure S1. Illustration of model building through the BioModelAnalyzer Graphic User 
Interface (BMA GUI). (A) Membrane bound receptors are depicted in green, intracellular 
stand-alone proteins are depicted in red, constant proteins and cell factors are depicted in 
grey, and interactions are depicted as either pointed (positive) or bar (negative) arrows. 
Reciprocal interactions, or two-directional edges, are supported (not depicted). (B) Several 
input proteins (b-e) influencing the value of a single protein (a).  
 
Figure S2. Stabilization analysis of the result found by Holtz et al. 2002 summarized in 
Table 1. (A) Base CP CML Model. (B) CP CML model after reducing the Bcr-Abl constant 
from 2 to 1. Note that in addition to the stable result of the proliferation phenotype shifting 
from 2 to 1, Apoptosis and Correct Differentiation shift from the stable values of 0 to 
oscillating between values 0 and 1, leading the entirety of the model to be labeled as a failure 
to reach stability. 
 
Table S1. List of nodes in the network.  Network ID refers to the internal label of the node. 
Proper name is Entrez name while Network Name is name given in construction of model. 
Cell fate is given for terminally‐downstream gene nodes. 
 
Table S2. List of edges in the network. BMA ID, Source ID, and Target ID refer to internal 
label of the node. 
 








KO1 and KO2 are the nodes knocked out identified by internal BMA ID as labeled in 
Supplementary Table 1 under the heading "Network ID." GA, SRC, A, P, CD are resulting 
phenotypes for the model - Growth Arrest, Self-Renewal Capacity, Apoptosis, Proliferation, 
and Correct Differentiation. A value of 0 corresponds to an extremely low or not present 
state of the phenotype and is labeled in red, a value of 1 is a moderate state and is labeled in 
yellow, and a value of 2 is a high state and is labeled in green.  
 
2nd Subtable:  
Columns represent model results where double KOs in each of the three base models (Wild 
Type (WT), Chronic Phase (CP) and Blast Crisis (BC)) resulted in the same values for the six 
phenotype nodes. A value of 1 corresponds to the same values and is labeled in green. A 
value of 0 corresponds to dissimilar values and is labeled in red.   
 
3rd Subtable:  
Columns represent model results where double KOs in each of the three base models 
resulted in a normal phenotype (corresponding to values of 0 for growth arrest, and 1 for 
each of the other phenotype nodes.) A value of 1 corresponds to when this occurs and is 
labeled in green. A value of 0 corresponds to when this does not occur and is labeled in red.   
 
4th Subtable:  
Columns represent model results where double KOs in each of the three base models 
resulted in a normal phenotype (as described in the "Third Subtable") for the WT model, and 
where CP and BC models showed reduced survival and proliferation, defined as when SRC 
is below 2, Apoptosis is above 0, Proliferation is below 2, and Correct Differentiation is 
below 2. A value of 1 corresponds to when this occurs and is labeled in green. A value of 0 
corresponds to when this does not occur and is labeled in red.   
 
Table S5. 
KO1 and KO2 are the nodes knocked out identified by internal BMA ID as labeled in 
Supplementary Table 2 under the heading "BMA ID." Please see the above legend for 








Figure S1. Illustration of model building through the BioModelAnalyzer Graphic User 
Interface (BMA GUI). (A) Membrane bound receptors are depicted in green, intracellular 
stand-alone proteins are depicted in red, constant proteins and cell factors are depicted in 
grey, and interactions are depicted as either pointed (positive) or bar (negative) arrows. 
Reciprocal interactions, or two-directional edges, are supported (not depicted). (B) Several 










Figure S2. Stabilization analysis of the result found by Holtz et al. 2002 summarized in 
Table 1. (A) Base CP CML Model. (B) CP CML model after reducing the Bcr-Abl constant 
from 2 to 1. Note that in addition to the stable result of the proliferation phenotype shifting 
from 2 to 1, Apoptosis and Correct Differentiation shift from the stable values of 0 to 
oscillating between values 0 and 1, leading the entirety of the model to be labeled as a failure 
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